Production of phospholipase A2 from recombinant yarrowia lipolytica biopharmaceutical application

Phospholipase A2 (PLA2) is an enzyme that catalyzes the hydrolyisis of glycerophospholipids at the sn-2 position to yield the corresponding lysophospholpids and the free fatty acids. It catalytic properties which act as powerful emulsifier make it a widely used enzyme in various industrial applicati...

Full description

Saved in:
Bibliographic Details
Main Author: Mokhtar, Nur'Ainun
Format: Thesis
Language:English
Published: 2013
Subjects:
Online Access:http://psasir.upm.edu.my/id/eprint/38650/1/FPSK%28m%29%202013%2031%20IR.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
id my-upm-ir.38650
record_format uketd_dc
spelling my-upm-ir.386502016-02-26T09:12:10Z Production of phospholipase A2 from recombinant yarrowia lipolytica biopharmaceutical application 2013-10 Mokhtar, Nur'Ainun Phospholipase A2 (PLA2) is an enzyme that catalyzes the hydrolyisis of glycerophospholipids at the sn-2 position to yield the corresponding lysophospholpids and the free fatty acids. It catalytic properties which act as powerful emulsifier make it a widely used enzyme in various industrial application including laboratories, cosmeticeuticals, food industry as well as in pharmaceutical. However, in most industries, the PLA2 used are mainly isolated from mammalian pancreas (bovine and porcine). On the contrary, it had come to an issue regarding the origin of this animal based product which are rejected due to religious concern and the risk of viral infections to the consumers. To prevail the issue, an alternative PLA2 to replace the commercially available PLA2 has been initiated. Optimization of production parameters such as temperature, initial pH, inoculums size, inducer concentration and agitation speed are investigated using Two-Level Factorial Design and Central Composite Design by Design-Expert®. From this study, the optimal conditions PLA2 production are 6% (v/v) inoculums size; agitation speed, 225 rpm; pH 5.8; temperature of 34.5oC; inducer concentration, 0.03% (v/v) in basal salt medium. A verification run and scale up of PLA2 production yield 26.22 mg/L and 19.07 mg/L respectively compared to 27.15 mg/L predicted by the model. Purification of this enzyme through freeze drying and ultrafiltration and have shown a satisfactory purification factor of 1.15 and 1.35, respectively. The enzymatic properties (optimum activity at 37oC, pH 8.0) of the recombinant produced PLA2 from Y. lipolytica in this study shows similar properties to that of commercially available PLA2 in market which indicate that this recombinant PLA2 is a good and remarkable alternative of PLA2 sources for biopharmaceutical usage especially for HALAL applications. Biopharmaceutics - instrumentation Technology, Pharmaceutical - instrumentation 2013-10 Thesis http://psasir.upm.edu.my/id/eprint/38650/ http://psasir.upm.edu.my/id/eprint/38650/1/FPSK%28m%29%202013%2031%20IR.pdf application/pdf en public masters Universiti Putra Malaysia Biopharmaceutics - instrumentation Technology, Pharmaceutical - instrumentation
institution Universiti Putra Malaysia
collection PSAS Institutional Repository
language English
topic Biopharmaceutics - instrumentation
Biopharmaceutics - instrumentation

spellingShingle Biopharmaceutics - instrumentation
Biopharmaceutics - instrumentation

Mokhtar, Nur'Ainun
Production of phospholipase A2 from recombinant yarrowia lipolytica biopharmaceutical application
description Phospholipase A2 (PLA2) is an enzyme that catalyzes the hydrolyisis of glycerophospholipids at the sn-2 position to yield the corresponding lysophospholpids and the free fatty acids. It catalytic properties which act as powerful emulsifier make it a widely used enzyme in various industrial application including laboratories, cosmeticeuticals, food industry as well as in pharmaceutical. However, in most industries, the PLA2 used are mainly isolated from mammalian pancreas (bovine and porcine). On the contrary, it had come to an issue regarding the origin of this animal based product which are rejected due to religious concern and the risk of viral infections to the consumers. To prevail the issue, an alternative PLA2 to replace the commercially available PLA2 has been initiated. Optimization of production parameters such as temperature, initial pH, inoculums size, inducer concentration and agitation speed are investigated using Two-Level Factorial Design and Central Composite Design by Design-Expert®. From this study, the optimal conditions PLA2 production are 6% (v/v) inoculums size; agitation speed, 225 rpm; pH 5.8; temperature of 34.5oC; inducer concentration, 0.03% (v/v) in basal salt medium. A verification run and scale up of PLA2 production yield 26.22 mg/L and 19.07 mg/L respectively compared to 27.15 mg/L predicted by the model. Purification of this enzyme through freeze drying and ultrafiltration and have shown a satisfactory purification factor of 1.15 and 1.35, respectively. The enzymatic properties (optimum activity at 37oC, pH 8.0) of the recombinant produced PLA2 from Y. lipolytica in this study shows similar properties to that of commercially available PLA2 in market which indicate that this recombinant PLA2 is a good and remarkable alternative of PLA2 sources for biopharmaceutical usage especially for HALAL applications.
format Thesis
qualification_level Master's degree
author Mokhtar, Nur'Ainun
author_facet Mokhtar, Nur'Ainun
author_sort Mokhtar, Nur'Ainun
title Production of phospholipase A2 from recombinant yarrowia lipolytica biopharmaceutical application
title_short Production of phospholipase A2 from recombinant yarrowia lipolytica biopharmaceutical application
title_full Production of phospholipase A2 from recombinant yarrowia lipolytica biopharmaceutical application
title_fullStr Production of phospholipase A2 from recombinant yarrowia lipolytica biopharmaceutical application
title_full_unstemmed Production of phospholipase A2 from recombinant yarrowia lipolytica biopharmaceutical application
title_sort production of phospholipase a2 from recombinant yarrowia lipolytica biopharmaceutical application
granting_institution Universiti Putra Malaysia
publishDate 2013
url http://psasir.upm.edu.my/id/eprint/38650/1/FPSK%28m%29%202013%2031%20IR.pdf
_version_ 1747811743731548160